联环药业：口服溶液1号生产线新建后首次通过药品 GMP 符合性检查

Group 1 - The company announced that its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd., received a notice of compliance inspection for drug GMP from the Anhui Provincial Drug Administration [1] - The inspection will focus on the oral solution dosage form, specifically the production line for oral solution No. 1, scheduled from June 4 to June 7, 2025 [1] - The inspection is based on the contract manufacturing of Ebastine oral solution (National Drug Approval No. H20243410) [1] Group 2 - As of the announcement date, the investment in the oral solution production line amounts to approximately RMB 7.5 million [1]